Weiyi Peng to Neoplasms
This is a "connection" page, showing publications Weiyi Peng has written about Neoplasms.
Connection Strength
1.885
-
LIMITing tumours with an immunogenic lncRNA. Nat Cell Biol. 2021 05; 23(5):443-445.
Score: 0.630
-
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 2021 02; 9(2).
Score: 0.619
-
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors. J Immunother Cancer. 2024 Sep 23; 12(9).
Score: 0.199
-
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med. 2023 Dec 19; 4(12):101326.
Score: 0.189
-
Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021 Jun; 11(6):1368-1397.
Score: 0.157
-
Development of a RIPK1 degrader to enhance antitumor immunity. Nat Commun. 2024 Dec 16; 15(1):10683.
Score: 0.051
-
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 Sep 23; 12(1):5606.
Score: 0.040